

Impurity Table 1

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Cyclopropylidaminopurine abacavir ^a	0.57	1.4	0.3
Descyclopropyl abacavir ^b	0.68	1.0	0.8
Abacavir	1.00	—	—
trans-Abacavir ^c	1.04	1.0	—
Any individual unspecified impurity	—	1.0	0.2

^a N⁶-Cyclopropyl-9H-purine-2,6-diamine.
^b [(1S,4R)-4-(2,6-Diamino-9H-purin-9-yl)cyclopent-2-enyl]methanol.
^c {(1R,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-cyclopent-2-enyl}methanol. It is a process impurity and monitored in the drug substance.

SPECIFIC TESTS

- MICROBIAL ENUMERATION TESTS** (61) and **TESTS FOR SPECIFIED MICROORGANISMS** (62): The total aerobic microbial count does not exceed 100 cfu/mL, and the total combined molds and yeast count does not exceed 10 cfu/mL. It also meets the requirement for absence of *Escherichia coli*.
- PH** (791): 3.8–4.5

ADDITIONAL REQUIREMENTS

- PACKAGING AND STORAGE:** Preserve in well-closed containers. Store at controlled room temperature.
- USP REFERENCE STANDARDS** (11)
 - USP Abacavir Sulfate RS
 - USP Abacavir System Suitability Mixture RS
 - A mixture containing abacavir sulfate and trans-abacavir

Abacavir Tablets

DEFINITION

Abacavir Tablets contain Abacavir Sulfate equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of abacavir (C₁₄H₁₈N₆O).

IDENTIFICATION

- A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

ASSAY

- PROCEDURE**
 - Diluent:** 1.0 mL of phosphoric acid in 1 L of water
 - Solution A:** Trifluoroacetic acid and water (0.05: 99.95)
 - Solution B:** Methanol and water (85:15)
 - Mobile phase:** See *Table 1*.

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	95	5
20	70	30
35	10	90
40	10	90
41	95	5
50	95	5

System suitability solution: 0.2 mg/mL of USP Abacavir System Suitability Mixture RS in *Diluent*

Standard solution: 0.21 mg/mL of abacavir sulfate in *Diluent* (equivalent to 0.18 mg/mL of abacavir), from USP Abacavir Sulfate RS

Sample stock solution: Transfer the equivalent to 1500 mg of abacavir, from a portion of Tablets, into a 250-mL volumetric flask. Add 150 mL of *Diluent*. Shake mechanically for 45 min. Dilute with *Diluent* to volume. Pass a portion through a suitable filter of 0.45-μm or finer pore size. Discard the first 3 mL of the filtrate.

Sample solution: 0.18 mg/mL of abacavir in *Diluent* using the filtrate obtained in the *Sample stock solution*

Chromatographic system
(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 254 nm

Column: 3.9-mm × 15-cm; packing L1

Flow rate: 0.8 mL/min

Injection volume: 10 μL

System suitability
Samples: *System suitability solution* and *Standard solution*

Suitability requirements
Resolution: NLT 1.5 between abacavir and trans-abacavir, *System suitability solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis
Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of abacavir (C₁₄H₁₈N₆O) in the portion of Tablets taken:

Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$

r_U = peak response of abacavir from the *Sample solution*

r_S = peak response of abacavir from the *Standard solution*

C_S = concentration of abacavir sulfate in the *Standard solution* (mg/mL)

C_U = nominal concentration of abacavir in the *Sample solution* (mg/mL)

M_{r1} = molecular weight of abacavir multiplied by 2, 572.66

M_{r2} = molecular weight of abacavir sulfate, 670.74

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

- DISSOLUTION** (711)
 - Medium:** 0.1 N hydrochloric acid; 900 mL
 - Apparatus 2:** 75 rpm
 - Time:** 15 min
 - Standard solution:** 0.39 mg/mL of USP Abacavir Sulfate RS in *Medium*
 - Sample solution:** Pass a portion of the solution under test through a suitable filter of 0.45-μm pore size.
 - Instrumental conditions**
 - Mode:** UV
 - Analytical wavelength:** 254 nm
 - Blank:** *Medium*
- Calculate the percentage of the labeled amount of abacavir (C₁₄H₁₈N₆O) dissolved:

Result = $(A_U/A_S) \times (C_S/L) \times (M_{r1}/M_{r2}) \times V \times 100$

A_U = absorbance of the *Sample solution*

A_S = absorbance of the *Standard solution*

C_S = concentration of the *Standard solution* (mg/mL)

L = label claim (mg/Tablet)

M_{r1} = molecular weight of abacavir multiplied by 2, 572.66

M_{r2} = molecular weight of abacavir sulfate, 670.74

V = volume of *Medium*, 900 mL

Tolerances: NLT 80% (Q) of the labeled amount of abacavir (C₁₄H₁₈N₆O) is dissolved.

USP Monographs